Immuron (NASDAQ:IMRN), an Australian biopharmaceutical company developing hyper-immune bovine colostrum-derived therapies for gastrointestinal and infectious diseases, on Wednesday released its half-year fiscal 2026 results for the period ended December 31, 2025, alongside a strategic reset announcement.
Global unaudited sales reached AUD$4.2 million, reflecting a 5% increase from the prior comparative period, driven primarily by growth in its flagship over-the-counter product Travelan (IMM-124E).
U.S. sales rose 17% year over year, supported by enhanced digital marketing, Amazon optimization and rising travel demand, while Australian sales contributed significantly to the overall performance.
The company ended the period with cash and cash equivalents of AUD$10 million, including net proceeds of AUD$7.3 million from a recent capital raise completed at an average price of A$0.0803 per share.
Meanwhile, Immuron emphasized progress on its validated Hyper-Immune platform technology, which generates polyclonal antibodies from immunized bovine colostrum for targeted gastrointestinal applications.
Key pipeline advancements include eligibility for an end-of-Phase 2 meeting with the U.S. Food and Drug Administration for IMM-124E (Travelan), aimed at formalizing a path toward potential registration for prevention of travelers' diarrhea, and FDA approval of an Investigational New Drug application for IMM-529, an adjunctive therapy targeting recurrent Clostridioides difficile infection in combination with standard antibiotics.
In a strategic reset, management stated the company will pursue partnerships to fund the ongoing clinical development of Travelan (IMM-124E) and IMM-529 programs, shifting from a fully self-funded model to one leveraging external collaboration to advance these assets while preserving cash resources for core operations and commercial growth.